GlassScriptPhysician profile
Santosh Kamath
NPI 1891933800
$2,124.98
in general payments reported to CMS, 2019-2025
31 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.74 · 2022: $950 · 2023: $525 · 2024: $322 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,141.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $242.83 | 2022-2025 | |
| Lilly USA, LLC | $241.45 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Abbvie INC. | $211.17 | 2021-2025 | |
| Pfizer INC. | $147.15 | 2022-2025 | |
| Exact Sciences Corporation | $141.60 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $131.34 | 2021-2025 | Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.67 | 2022-2024 | Xifaxan |
| Mylan Specialty L.P. | $108.00 | 2022 | |
| Amgen INC. | $95.12 | 2022-2024 | Evenity, Prolia, Otezla |
| Medtronic, INC. | $77.77 | 2025 | Protege Rx |
| Dexcom, INC. | $72.43 | 2022-2024 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $42.66 | 2023 | Quviviq |
| Astellas Pharma US INC | $42.20 | 2022-2023 | Myrbetriq |
| Novo Nordisk INC | $39.16 | 2025 | Ozempic, Rybelsus |
| Averitas Pharma INC. | $36.55 | 2023 | Qutenza |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.49 | 2022-2024 | Tradjenta, Jardiance |
| Otsuka America Pharmaceutical, INC. | $34.21 | 2023 | Nuedexta, Rexulti |
| Sumitomo Pharma America, INC. | $33.94 | 2023-2024 | Gemtesa |
| Grt US Holding, INC. | $33.38 | 2022 | |
| Nevro Corp. | $27.86 | 2023 | Senza |
| Sunovion Pharmaceuticals INC. | $26.34 | 2022 | |
| Amarin Pharma, INC. | $23.50 | 2022 | |
| Janssen Pharmaceuticals, INC | $23.19 | 2022 | |
| Si-Bone, INC. | $22.03 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.34 | 2022 | |
| Esperion Therapeutics, INC. | $20.16 | 2022 | |
| Boston Scientific Corporation | $19.00 | 2024 | Watchman Access System |
| Glaxosmithkline, LLC. | $17.86 | 2022 | |
| Saluda Medical Americas, INC. | $17.69 | 2024 | Evoke |
| Smith+Nephew, INC. | $15.24 | 2022 | |
| Lundbeck LLC | $14.65 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Santosh Kamath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.